|
Manhattan Isotope inks cyclotron agreement
 November 17, 2011 -- Manhattan Isotope Technology, with the support of molecular imaging developer Positron, has signed a memorandum of understanding with the ARRONAX cyclotron facility in Nantes, France, that will allow the firms to collaborate on the production of strontium-82 and other medical radionuclides.
To view the remainder of this article, and other exclusive content, you must first sign-in or register using the options below.
(Helptag:PaywallArticleLoginMessage)
| |
|
|
New AuntMinnie.com Members
|
Becoming a Member is FREE!
|
Real-time radiology-specific news
Case of the Day and Teaching Files
Focused topics digital communities
Lively, discussion groups
Medical imaging bookstore
SalaryScan
Job Boards
OnLine CMe/CE
Bookstore, market reports, more …
Conference Calendar
User-controlled eNewsletters
… registration is FREE and easy!
|
| |
|
Positron expects Sr-82 validation samples to begin arriving from ARRONAX (Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic) to Manhattan Isotope's Lubbock, TX, processing facility in early 2012, with the filing of a drug master file with the U.S. Food and Drug Administration (FDA) in the spring. Currently, the only supplier of active pharmaceutical ingredient (API)-grade strontium-82 in the U.S. is the U.S. Department of Energy, Positron said.
Earlier this month, Positron moved to acquire Manhattan Isotope Technology; the deal is scheduled to close on January 2, 2012, after final transaction documents are executed. | |
|